Per the company, full data will be revealed at the American Diabetes Association (ADA) meeting in June
Animal studies showed that exposure to GLP1-RAs was associated with small-for-gestational age pups (birthweight that is lower than expected at the time of delivery), and there was an increased risk of birth defects compared to unexposed animals
Schmidt-Sommerfeld E, Penn D, Wolf H
This includes: Fasting blood sugar levels Post-meal readings Hemoglobin A1C results (if available) Tracking your blood sugar helps your doctor understand how well your current treatment is working and whether adding tirzepatide might improve your results
283 ObolenskyABerenshteinELedermanMBulvikBAlper-PinusRYaulRet al
Reported complications described in some GLP-1 drug claims have included: Severe or persistent gastrointestinal symptoms , such as ongoing nausea, vomiting, or abdominal pain Delayed stomach emptying (gastroparesis) , which has been described by some individuals as involving bloating, nausea, vomiting, or difficulty tolerating food Intestinal complications , including reduced bowel activity (ileus), which may involve abdominal discomfort, cramping, or vomiting Gallbladder-related conditions , such as gallstones or gallbladder inflammation Blood-clot-related conditions , including deep vein thrombosis or pulmonary embolism, described in some reports and legal filings Vision-related problems , including reports involving non-arteritic anterior ischemic optic neuropathy (NAION) discussed in connection with semaglutide in certain contexts Not everyone who takes a GLP-1 medication experiences these issues, and the relationship between GLP-1 drugs and reported complications continues to be evaluated in legal proceedings
